A clinical briefing for providers on Bijuva availability in 2026, prescribing considerations, alternatives, and tools to help patients access their medication.
Bijuva (Estradiol and Progesterone capsules) occupies a unique position in the menopause hormone therapy landscape as the only FDA-approved combination of bioidentical estradiol and bioidentical progesterone. While patient interest in this product continues to grow, providers should be aware of the ongoing availability challenges that can complicate prescribing and patient adherence.
This briefing covers the current supply picture, prescribing implications, cost and access considerations, and clinical tools to help your patients get the medication they need.
Understanding the supply history provides context for current challenges:
The manufacturer transition, combined with Bijuva's brand-only status and 24 active patents, has contributed to a fragmented supply landscape. Wholesale availability is generally adequate, but many retail pharmacies — particularly large chains — do not routinely stock the product.
The availability situation creates several clinical considerations for prescribers:
When patients cannot easily fill their Bijuva prescription, gaps in therapy are common. Interruptions in menopausal hormone therapy can lead to symptom recurrence and patient frustration. Providers should proactively discuss contingency plans when prescribing Bijuva.
Bijuva is available in two strengths: 0.5 mg estradiol/100 mg progesterone and 1 mg estradiol/100 mg progesterone. The prescribing information recommends starting with the lower dose and titrating up based on clinical response. Both strengths may face similar availability constraints.
Many commercial insurance plans and Medicare Part D formularies require prior authorization for Bijuva, and some mandate step therapy with a less expensive combination HRT product (e.g., generic Activella or Prempro) before approving Bijuva. Providers should be prepared to document clinical rationale for Bijuva-specific therapy, particularly the FDA-approved bioidentical combination aspect.
Key data points for providers counseling patients:
Cost is a significant barrier to access for many patients:
By comparison, generic Estradiol tablets (1 mg) plus generic Progesterone capsules (100 mg) taken as separate prescriptions typically cost $25–$70/month combined, making this the most cost-effective bioidentical alternative.
Several resources can streamline patient access to Bijuva:
Medfinder allows providers and their staff to search for pharmacies with Bijuva in stock near the patient's location. This is particularly useful when patients report difficulty filling their prescription.
For patients with financial hardship, the following resources may help:
When Bijuva cannot be obtained, consider these therapeutic alternatives:
For a patient-facing version of this information, see our article on alternatives to Bijuva.
Several trends will shape Bijuva access in the coming years:
Bijuva remains an important option in the menopausal HRT toolkit — it is the only FDA-approved bioidentical estradiol/progesterone combination, and many patients specifically seek it out. However, prescribers should set realistic expectations about availability, proactively discuss cost-saving strategies, and have alternative treatment plans ready.
Use Medfinder for Providers to help your patients locate Bijuva in stock, and direct patients to our guides on finding Bijuva and saving on Bijuva for additional support.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
